A phase I randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and immunogenicity of a live-attenuated quadrivalent dengue vaccine in flavivirus-naïve and flavivirus-experienced healthy adults
Kevin L. Russell, Richard Rupp, Javier O Morales-Ramirez, Clemente Díaz-Pérez, Charles P. Andrews, Andrew W. Lee, Tyler S. Finn, Kara S. Cox, Amy Falk Russell, Margaret M. Schaller, Jason Martin, Donna Hyatt, Sabrina Gozlan-Kelner, Androniki Bili, Beth-Ann Coller
Abstract
GMTs were observed after the first vaccination with TV003 and TV005 in both flavivirus subgroups for all dengue serotypes, and minimal increases were measured PD2. GMTs in the TV003 and TV005 BFE and BFN groups remained above the respective baselines and placebo through 1-year PD2. These data support further development of V181 as a single-dose vaccine for the prevention of dengue disease.
Topics & Concepts
Dengue vaccineFlavivirusTolerabilityDengue feverDengue virusImmunogenicityPlacebomyalgiaVirologyMedicineVaccinationReactogenicityAdverse effectImmunologyPlaque reduction neutralization testInternal medicineVirusImmune systemNeutralizationPathologyAlternative medicineMosquito-borne diseases and controlMalaria Research and ControlViral Infections and Vectors